At the AACR Annual Meeting 2025, PamGene presented six scientific posters showcasing how our kinase activity profiling technology accelerates drug discovery and enhances understanding of cancer biology. These studies demonstrate the broad applicability of our KinomePro platform—from biomarker discovery to evaluating novel therapeutic candidates. Visit us at Booth #3355
Poster Highlights:
- OMX-0407 in RCC and Sarcomas
Demonstrated dose-dependent kinase modulation, G1 cell cycle arrest, and immune-related effects in preclinical models. - WBMP-4 Antibody Discovery Platform
Identified BCR-targeting monoclonal antibody WBMP-4, showing extensive kinase inhibition and induction of apoptosis in lymphoma cells. - Kinase Pathway Regulation in Hypoxic Melanoma
Mapped how IFNγ and TNFα signaling pathways are reshaped by hypoxia, revealing insights into immune evasion strategies. - Pharmacodynamic Biomarkers for OMX-0407
Validated kinase inhibition and anti-tumor effects in solid tumors, including a complete response in angiosarcoma. - Colorectal Cancer Subtyping by Kinase Activity
Defined distinct kinase-driven subgroups with therapeutic relevance and response predictions based on kinase signatures. - Integrative Profiling in Melanoma Cell Lines
Combined kinomic and transcriptomic analyses to identify pathway shifts related to metastatic potential and drug sensitivity.
These studies highlight PamGene’s commitment to advancing functional precision oncology by enabling detailed kinase activity analysis in biologically relevant models.
View all posters and abstracts here: LINK
